10 November 2022 
EMA/862229/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
DuoPlavin 
clopidogrel / acetylsalicylic acid 
On  10  November 2022,  the  Committee for  Medicinal Products  for Human  Use  (CHMP)  adopted  a positive 
opinion  recommending a  change  to  the  terms  of  the  marketing  authorisation  for  the  medicinal  product 
DuoPlavin. The marketing authorisation  holder for this medicinal product is sanofi-aventis groupe. 
The  CHMP  adopted  a  change  to  the  existing  indication  to  include  the  secondary  prevention  of 
atherothrombotic  events  in  patients  with  ST  segment  elevation  acute  myocardial  infarction  (STEMI) 
undergoing percutaneous coronary intervention (PCI): 
” 
For information, the full indications  for DuoPlavin will  be as follows: 2 
DuoPlavin is indicated  for the  secondary prevention of atherothrombotic events  in  adult  patients 
already  taking  both  clopidogrel  and  acety lsalicylic  acid  (ASA).  DuoPlavin  is  a  fixed-dose 
combination medicinal product for continuation  of therapy in: 
•  Non-ST  segment  elevation  acute  coronary  syndrome  (unstable  angina  or   non-Q-wave 
myocardial infarction) including patients undergoing a stent placement following percutaneous 
coronary intervention (PCI) 
•  ST  segment  elevation  acute  myocardial  infarction  (STEMI)  in  patients  undergoing  PCI 
(including patients undergoing a stent placement)  or medically treated patients eligible 
for thrombolytic/ fibrinolytic therapy 
For further information please refer to section 5.1. 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which  will  be published in  the revised European public  assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union    
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
